Abstract
Background The WHO End TB Strategy requires universal drug susceptibility testing and treatment of all people with tuberculosis. However, available second-line diagnostic tools are cumbersome and require sophisticated laboratory infrastructure, and ultimately less than half of those with drug-resistant tuberculosis receive appropriate treatment. Xpert MTB/XDR was developed to help overcome these limitations.
Methods We assessed the diagnostic accuracy of sputum-based Xpert MTB/XDR for isoniazid, fluoroquinolone, ethionamide and second-line injectable resistance detection in adults with an Xpert MTB/RIF or Ultra Mycobacterium tuberculosis-positive result against a composite reference standard of phenotypic drug-susceptibility testing and whole genome sequencing (NCT03728725). Participants with pulmonary tuberculosis symptoms and ≥1 risk factor for drug resistance were consecutively enrolled between four clinical sites in India, Moldova and South Africa.
Findings Between 31 July 2019 and 21 March 2020, we enrolled 710 patients, of which 611 (86.1%) had results from index and composite reference standard tests and were included in analysis. The sensitivity of Xpert MTB/XDR was 94% for isoniazid, 95% for fluoroquinolones, 54% for ethionamide, 73% for amikacin, 86% for kanamycin, and 61% for capreomycin resistance detection. Specificity was 98-100% for all drugs. Performance was equivalent to line-probe assays. The non-determinate rate of Xpert MTB/XDR was 2·96%.
Interpretation This first prospective, multicentre clinical study of the Xpert MTB/XDR assay demonstrated high diagnostic test accuracy, meeting target product profile criteria for a next-generation drug susceptibility test.
Funding German Federal Ministry of Education and Research through KfW, Dutch Ministry of Foreign Affairs, and Australian Department of Foreign Affairs and Trade.
Evidence before this study The World Health Organization (WHO) has highlighted the development of expanded, rapid molecular drug susceptibility tests as a key priority to tackle drug-resistant tuberculosis (TB). Prior to the Cepheid Xpert MTB/XDR assay, the only WHO-recommended rapid molecular assay for second-line resistance detection was the Bruker-Hain GenoType MTBDRsl line probe assay. However, the high complexity of DNA-based hybridization assays limits their use to central reference or regional-level laboratories where the appropriate infrastructure and user expertise can be ensured. In this context, the Xpert MTB/XDR assay is the only lower complexity, automated molecular assay for broader resistance detection suitable for use at lower levels of the laboratory network. We searched PubMed databases for articles evaluating the performance of the sputum-based assay using search terms (tuberculosis or TB) AND (Xpert OR GeneXpert OR cartridge) AND (second-line OR XDR OR “extensively drug-resistant”) AND (sputum OR sputa) AND (test OR assay OR diagnostic OR “point of care”) AND (performance OR accuracy OR sensitivity OR specificity OR diagnos*). The search was done on 8 Feb 2021 with no search date or language restrictions. Our search yielded 51 studies, of which only three reported on a sputum-based cartridge for expanded resistance detection. The first two studies described the assay design approach and reported initial performance metrics for a prototype version of the Xpert MTB/XDR assay. In the third study, the manufacturer demonstrated high performance for the final assay (sensitivity of 94–100% and a specificity of 100% for all drugs except for ethionamide) when compared with sequencing for 314 sputum specimens and sediments. This study was the first assessment of Xpert MTB/XDR assay diagnostic accuracy in a prospective patient cohort.
Added value of this study This is the first clinical study of the diagnostic performance of the Xpert MTB/XDR assay for expanded drug resistance detection. This study was performed independent of the manufacturer in settings of intended use utilizing prospectively collected primary clinical samples. The study employed a comprehensive reference standard using both phenotypic drug susceptibility testing and whole genome sequencing separately, as well as in combination, which allowed a differentiated view of performance of the assay for resistance detection. Moreover, we compared the performance of the assay on direct sputum samples with the performance of the WHO-recommended Bruker-Hain MTBDRplus and MTBDRsl line probe assays on culture.
Implications of all the available evidence The WHO End TB Strategy calls for early diagnosis and universal access to drug susceptibility testing. With a 10-color calibration to GeneXpert instruments, the Xpert MTB/XDR assay expands upon the drug detection landscape of the Xpert MTB/RIF and Ultra assays and overcomes the limitations of the Bruker-Hain line probe assays to offer an option for lower-level health care centres to conduct rapid, expanded drug susceptibility testing in follow-up to a TB-positive result using existing laboratory infrastructure. Data from this study demonstrates that the Xpert MTB/XDR assay has high performance for a diverse clinical population in the intended setting of use, providing national TB programmes with a valuable tool for expanded drug susceptibility testing for all persons with signs and symptoms of TB.
Competing Interest Statement
APN, CMD, MR, SBG, and SGS are employed by the Foundation for Innovative New Diagnostics (FIND). FIND is a not-for-profit foundation that supports the evaluation of publicly prioritized tuberculosis assays and the implementation of WHO-approved (guidance and prequalification) assays using donor grants. FIND has product evaluation agreements with several private sector companies that design diagnostics for tuberculosis and other diseases. These agreements strictly define FIND's independence and neutrality with regard to these private sector companies.
Clinical Trial
NCT03728725
Funding Statement
German Federal Ministry of Education and Research through KfW, Dutch Ministry of Foreign Affairs, and Australian Department of Foreign Affairs and Trade. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This prospective, multicentre, cross-sectional diagnostic accuracy study (NCT03728725) was sponsored by FIND and conducted with full institutional review board and independent ethics committees approvals from the Ethics Committee of Research - Phthisiopneumology Institute Chiril Draganiuc, Ministry of Health, Labour and Social Protection of the Republic of Moldova in Chisinau Moldova; the P.D. Hinduja Hospital and Medical Research Centre Institutional Review Board in Mumbai, India; the Ethics Committee of the National Institute of Tuberculosis and Respiratory Diseases (NITRD) in New Delhi, India; and the Human Research Ethics Committee (Medical) of the University of the Witwatersrand in Johannesburg, South Africa. The study was conducted in accordance with the 1964 Helsinki declaration and all participants provided informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** The members of the Xpert XDR Trial Consortium are listed at the end of this paper.
Data Availability
Individual, de-identified participant data will be shared, including data dictionaries. Other documents that have been made available include the study protocol and statistical analysis plan. Templates of the informed consent forms may be shared upon request. The data will be available immediately following publication with no end date. The data will be shared with anyone who wishes to access the data. The data will be available for any purpose of analyses. For data, please contact the corresponding author.
